agilon health inc - AGL
AGL
Close Chg Chg %
0.63 0.02 2.82%
Closed Market
0.65
+0.02 (2.82%)
Volume: 5.53M
Last Updated:
Feb 6, 2026, 3:59 PM EDT
Company Overview: agilon health inc - AGL
AGL Key Data
| Open $0.63 | Day Range 0.63 - 0.67 |
| 52 Week Range 0.51 - 6.08 | Market Cap $286.06M |
| Shares Outstanding 414.58M | Public Float 304.15M |
| Beta 0.07 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.78 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 6.58M |
AGL Performance
| 1 Week | -22.13% | ||
| 1 Month | -34.68% | ||
| 3 Months | -2.88% | ||
| 1 Year | -80.54% | ||
| 5 Years | N/A |
AGL Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
17
Full Ratings ➔
About agilon health inc - AGL
Agilon Health, Inc. engages in the provision of healthcare services. It also provides capital, data, payor relationships, executive experience, and contract support that allow physician groups to take on the risk of total care for their patients. The company was founded by Ronald A. Williams and Veeral Desai in 2016 and is headquartered in Westerville, OH.
AGL At a Glance
Agilon Health, Inc.
440 Polaris Parkway
Westerville, Ohio 43082
| Phone | 1-562-256-3800 | Revenue | 6.06B | |
| Industry | Medical/Nursing Services | Net Income | -251,388,000.00 | |
| Sector | Health Services | 2024 Sales Growth | 40.408% | |
| Fiscal Year-end | 12 / 2025 | Employees | 1,076 | |
| View SEC Filings |
AGL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.129 |
| Price to Book Ratio | 1.663 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.615 |
| Enterprise Value to Sales | 0.069 |
| Total Debt to Enterprise Value | 0.105 |
AGL Efficiency
| Revenue/Employee | 5,632,462.825 |
| Income Per Employee | -233,631.97 |
| Receivables Turnover | 5.959 |
| Total Asset Turnover | 3.488 |
AGL Liquidity
| Current Ratio | 1.265 |
| Quick Ratio | 1.265 |
| Cash Ratio | 0.352 |
AGL Profitability
| Gross Margin | -0.324 |
| Operating Margin | -4.685 |
| Pretax Margin | -4.106 |
| Net Margin | -4.148 |
| Return on Assets | -14.408 |
| Return on Equity | -44.197 |
| Return on Total Capital | -48.615 |
| Return on Invested Capital | -41.121 |
AGL Capital Structure
| Total Debt to Total Equity | 9.335 |
| Total Debt to Total Capital | 8.538 |
| Total Debt to Total Assets | 2.535 |
| Long-Term Debt to Equity | 8.813 |
| Long-Term Debt to Total Capital | 8.06 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Agilon Health Inc - AGL
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 1.83B | 2.71B | 4.32B | 6.06B | |
Sales Growth
| +50.50% | +47.70% | +59.38% | +40.41% | |
Cost of Goods Sold (COGS) incl D&A
| 1.77B | 2.61B | 4.26B | 6.08B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 14.67M | 13.77M | 20.16M | 24.46M | |
Depreciation
| 2.77M | 4.07M | 12.16M | 12.20M | |
Amortization of Intangibles
| 11.90M | 9.70M | 8.00M | 12.26M | |
COGS Growth
| +55.72% | +47.30% | +63.34% | +42.63% | |
Gross Income
| 61.87M | 98.51M | 53.63M | (19.62M) | |
Gross Income Growth
| -23.26% | +59.23% | -45.56% | -136.59% | |
Gross Profit Margin
| +3.37% | +3.64% | +1.24% | -0.32% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 442.96M | 216.47M | 285.57M | 264.33M | |
Research & Development
| - | - | - | - | - |
Other SG&A
| 442.96M | 216.47M | 285.57M | 264.33M | |
SGA Growth
| +222.64% | -51.13% | +31.92% | -7.44% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 12.86M | 7.93M | 188.00K | 8.17M | |
EBIT after Unusual Expense
| (393.95M) | (125.89M) | (232.13M) | (292.13M) | |
Non Operating Income/Expense
| (4.50M) | 24.73M | 44.33M | 49.48M | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | 16.49M | 14.99M | - |
Interest Expense
| 6.15M | 4.53M | 6.66M | 6.18M | |
Interest Expense Growth
| -24.45% | -26.37% | +47.14% | -7.22% | |
Gross Interest Expense
| 6.15M | 4.53M | 6.66M | 6.18M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (404.60M) | (105.69M) | (194.46M) | (248.83M) | |
Pretax Income Growth
| -548.99% | +73.88% | -83.99% | -27.96% | |
Pretax Margin
| -22.07% | -3.90% | -4.51% | -4.11% | |
Income Tax
| 886.00K | 1.64M | 791.00K | 1.45M | |
Income Tax - Current - Domestic
| 1.29M | 1.11M | 1.50M | (18.00K) | |
Income Tax - Current - Foreign
| - | - | 893.00K | 1.25M | - |
Income Tax - Deferred - Domestic
| (403.00K) | 530.00K | (1.47M) | 357.00K | |
Income Tax - Deferred - Foreign
| - | - | (134.00K) | (142.00K) | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | 16.49M | 14.99M | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (405.48M) | (107.33M) | (195.25M) | (250.28M) | |
Minority Interest Expense
| (300.00K) | (311.00K) | (207.00K) | 50.00K | |
Net Income
| (405.18M) | (107.02M) | (195.05M) | (250.33M) | |
Net Income Growth
| -541.03% | +73.59% | -82.26% | -28.34% | |
Net Margin Growth
| -22.10% | -3.95% | -4.52% | -4.13% | |
Extraordinaries & Discontinued Operations
| (1.78M) | 465.00K | (20.00M) | (1.06M) | |
Discontinued Operations
| (1.78M) | 465.00K | (20.00M) | (1.06M) | |
Net Income After Extraordinaries
| (406.96M) | (106.55M) | (215.05M) | (251.39M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (406.96M) | (106.55M) | (215.05M) | (251.39M) | |
EPS (Basic)
| -1.0172 | -0.2611 | -0.5259 | -0.6117 | |
EPS (Basic) Growth
| -394.27% | +74.33% | -101.42% | -16.31% | |
Basic Shares Outstanding
| 400.10M | 408.15M | 408.92M | 410.97M | |
EPS (Diluted)
| -1.0172 | -0.2611 | -0.5259 | -0.6117 | |
EPS (Diluted) Growth
| -394.27% | +74.33% | -101.42% | -16.31% | |
Diluted Shares Outstanding
| 400.10M | 408.15M | 408.92M | 410.97M | |
EBITDA
| (366.42M) | (104.19M) | (211.78M) | (259.49M) | |
EBITDA Growth
| -760.67% | +71.57% | -103.27% | -22.53% | |
EBITDA Margin
| -19.98% | -3.85% | -4.91% | -4.28% |
Snapshot
| Average Recommendation | HOLD | Average Target Price | 0.986 | |
| Number of Ratings | 17 | Current Quarters Estimate | -0.02 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | -0.393 | |
| Last Quarter’s Earnings | -0.28 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.781 | Next Fiscal Year Estimate | -0.235 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 11 | 11 | 17 | 12 |
| Mean Estimate | -0.02 | -0.11 | -0.39 | -0.24 |
| High Estimates | 0.09 | -0.05 | -0.17 | -0.03 |
| Low Estimate | -0.13 | -0.18 | -0.52 | -0.41 |
| Coefficient of Variance | -325.21 | -40.16 | -23.12 | -45.60 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 2 | 2 | 2 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 13 | 13 | 14 |
| UNDERWEIGHT | 1 | 1 | 1 |
| SELL | 1 | 1 | 1 |
| MEAN | Hold | Hold | Hold |
SEC Filings for Agilon Health Inc - AGL
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Agilon Health Inc - AGL
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Apr 4, 2025 | Steven J. Sell CEO & President; Director | 906,781 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Steven J. Sell CEO & President; Director | 865,385 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Jeffrey A. Schwaneke Chief Financial Officer | 22,300 | Open market or private purchase of non-derivative security Non-derivative transaction at $11.22 per share | 250,206.00 |
| Apr 4, 2025 | Jeffrey A. Schwaneke Chief Financial Officer | 1,130,552 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Jeffrey A. Schwaneke Chief Financial Officer | 673,077 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Girish Venkatachaliah Chief Technology Officer | 277,670 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Girish Venkatachaliah Chief Technology Officer | 192,308 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Benjamin Shaker Chief Markets Officer | 885,980 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Benjamin Shaker Chief Markets Officer | 673,077 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Denise V. Zamore Chief Legal Officer | 450,047 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Denise V. Zamore Chief Legal Officer | 384,616 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Timothy Gertsch Chief Accounting Officer | 119,035 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Timothy Gertsch Chief Accounting Officer | 96,154 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |